Posted by Michael Wonder on 14 Jun 2021
Opdivo plus Yervoy scores NICE backing for certain bowel cancer patients
14 June 2021 - Bristol Myers Squibb’s immunotherapy combination Opdivo plus Yervoy has been recommended by NICE for the treatment of certain advanced bowel cancer patients.
In its final appraisal document, NICE has recommended Opdivo (nivolumab) plus Yervoy (ipilimumab) for advanced bowel cancer patients with the rare high microsatellite instability or mismatch repair deficiency mutations following failed fluoropyrimidine-based chemotherapy.
